Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia

AstraZeneca4,875 enrolled

Overview

The purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of Coronary heart disease compared to atorvastatin and simvastatin alone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

4,875

Conditions

Hypercholesterolemia

Interventions

RosuvastatinDRUG

AtorvastatinDRUG

SimvastatinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Discontinuation of all cholesterol lowing drugs, including dietary supplements. * Documented history of, or high risk of coronary heart disease or other established atherosclerotic disease. Exclusion Criteria: * The use of lipid lowering drugs or dietary supplements after Visit 1. * Active arterial disease eg Unstable angina, or recent arterial surgery * Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse. * Abnormal laboratory parameters as defined in the protocol.

Outcomes

Primary Outcomes

Low density Lipoprotein cholesterol level - reaching internationally recognised LDL cholesterol goal levels.

Time frame: 16 weeks

Secondary Outcomes

Percentage change in other cholesterol & triglyceride measures

Time frame: 16 weeks

Safety evaluation

Time frame: 8 & 16 weeks

To compare the efficacy of rosuvastatin with atorvastatin and simvastatin

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.